Multichannel
How US pharma is charting a new course in a changed world
Post-Trump and post pandemic, pharma in the US is eyeing emerging commercial and clinical opportunities, but must reckon with potential storms ahead
More Articles
Medical
Redefining the role of the MSL in a changed world
MSLs will need to respond to the growing demands being placed on them in the new normal by adopting new approaches, capabilities and skill sets
Commercial
Accelerating commercial success in CAGT
To build on the successes thus far in cell and gene therapy, pharma must foster further payer, physician and patient buy-in
Clinical
Lowering the patient burden in clinical trials
Closer relationships with patients and a better understanding of what matters to them will show the way improving their experience of trials
Clinical
Is COVID the gamechanger for decentralized trials?
There is a golden opportunity to deliver clinical trial innovation post-pandemic given healthcare’s appetite for new approaches, such as virtual patient consults and more efficient trial designs
Patients and Medical
The value in measuring the patient experience
Pharma can improve outcomes, products and HCP relationships using technology to capture patients’ day-to-day experience of their disease
Multichannel
Building capacity in digital
The new era of digital-first engagement demands new approaches to scaling by harnessing technology, seeing content creation as collaborative and cultivating a startup culture
Access and Evidence
Bringing innovation to rare disease patients in Europe
Johanna Friedl-Naderer, President, Europe, Canada & Partner Markets, Biogen on how collaboration between governments and industry can lead to better patient outcomes.
Access and Evidence
#Icare4Rare campaign launches to raise awareness ahead of Rare Disease Week 2021
To help raise awareness of rare disease, Reuters Events, Biogen and EU40 have collaborated to launch the #Icare4rare campaign to give prominence to Rare Disease Week 2021
Clinical
Trial site management in the post pandemic era
The impacts of 2020 on trials are causing pharma to consider a new direction for trial sites, taking them closer to the patient